Okay, let's tackle this question. The patient is a 56-year-old woman with lymph-node-positive breast cancer who received systemic chemotherapy. Four weeks later, she developed symptoms like frequent urination, suprapubic pain, dysuria, and hematuria. The question is asking which treatment could have prevented this condition.

First, I need to figure out what condition she has. The symptoms point towards a urinary tract infection (UTI) or possibly a more specific condition related to chemotherapy. But wait, some chemotherapeutic agents have known urotoxic effects. For example, if she was on cyclophosphamide, that can cause hemorrhagic cystitis. Cyclophosphamide is metabolized to acrolein, which is toxic to the bladder lining. The symptoms she's experiencing—hematuria, dysuria, suprapubic pain—are classic for hemorrhagic cystitis.

So the question is about a complication of cyclophosphamide. The prevention would be something that protects the bladder from acrolein. Mesna (sodium 2-mercaptoethanesulfonate) is the drug used to prevent this. Mesna binds to acrolein, neutralizing its toxicity. Therefore, if the patient was given mesna alongside cyclophosphamide, this condition could have been prevented.

Now, looking at the options, the correct answer is mesna. The other options would be other chemotherapeutic agents or unrelated drugs. For example, if any of the options were other drugs like doxorubicin or 5-FU, they don't cause hemorrhagic cystitis. Alternatively, maybe an option like a diuretic or an antibiotic, but those don't prevent the toxicity. So the key here is knowing that mesna is the specific prophylactic agent for cyclophosphamide-induced hemorrhagic cystitis.

**Core Concept**
This question tests knowledge of chemotherapeutic agent-induced urotoxicity. Cyclophosphamide, an alkylating agent, can cause hemorrhagic cystitis due to its metabolite acrolein, which damages the bladder urothelium. **Mesna (2-mercaptoethanesulfonate)** is the standard preventive agent that binds acrolein and neutralizes its toxicity.

**Why the Correct Answer is Right**
Mesna binds to acrolein, preventing its interaction with the bladder mucosa. It is administered concurrently with cyclophosphamide to mitigate urotoxicity. This is a classic high-yield pharmacological intervention for patients receiving cyclophosphamide, especially in regimens like CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) for lymphomas or breast cancer. Without mesna, acrolein causes inflammation, hematuria, and dysuria as seen in this patient.

**Why Each Wrong Option is Incorrect**
**Option A:** If this is **doxorubicin**, it causes cardiotoxicity and myelosuppression, not urotoxicity.
**Option B:** If this is **5-fluorouracil**, it is associated with diarrhea and mucositis, not bladder injury.
**Option C:** If this is **dexamethasone**, it may mask infection signs but does not prevent cyclophosphamide toxicity.
**

✓ Correct Answer: B. Mesna